| Date Filed | Type | Description |
| 08/22/2023 |
4
| Kandera Reinhard (CFO) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Bought 7,000 shares
@ $0.725, valued at
$5.1k
|
|
| 08/17/2023 |
4
| Kandera Reinhard (CFO) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Bought 8,000 shares
@ $0.714, valued at
$5.7k
|
|
| 08/10/2023 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/11/2023 |
4
| Aldag Jorn (CEO) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Bought 5,000 shares
@ $0.81, valued at
$4.1k
Bought 5,000 shares
@ $0.8284, valued at
$4.1k
|
|
| 07/07/2023 |
4
| Aldag Jorn (CEO) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Bought 5,000 shares
@ $0.89, valued at
$4.5k
|
|
| 07/05/2023 |
4
| Aldag Jorn (CEO) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Bought 5,000 shares
@ $0.8911, valued at
$4.5k
|
|
| 07/03/2023 |
4
| Kandera Reinhard (CFO) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Bought 12,000 shares
@ $0.88, valued at
$10.6k
|
|
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
4
| Peters Malte (Director) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Granted 52,000 options to buy
@ $1.01, valued at
$52.5k
|
|
| 06/09/2023 |
4
| Reilly Timothy P. (Director) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Granted 26,000 options to buy
@ $1.01, valued at
$26.3k
|
|
| 06/09/2023 |
4
| O'Neill Julie (Director) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Granted 26,000 options to buy
@ $1.01, valued at
$26.3k
|
|
| 06/09/2023 |
4
| van de Winkel Jan (Director) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Granted 52,000 options to buy
@ $1.01, valued at
$52.5k
|
|
| 06/09/2023 |
4
| Kaufman David Ross (Director) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Granted 26,000 options to buy
@ $1.01, valued at
$26.3k
|
|
| 06/09/2023 |
4
| Coelho Mary Theresa (Director) has filed a Form 4 on HOOKIPA Pharma Inc.|
Txns:
| Granted 52,000 options to buy
@ $1.01, valued at
$52.5k
|
|
| 06/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...|
Docs:
|
"UNDERWRITING AGREEMENT",
"HOOKIPA PHARMA INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW HOOKIPA PHARMA INC., a Delaware corporation , in accordance with the provisions of Section 103 of the Delaware General Corporation Law does hereby certify that, in accordance with Sections 141 and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation on May 30, 2023: RESOLVED, pursuant to authority expressly set forth in the Amended and Restated Certificate of Incorporation of the Corporation , the issuance of a series of Preferred Stock designated as the Series A-2 Convertible Preferred Stock, par value $0.0001 per share, of the Corpora...",
"The New York Times Building",
"HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, May 31, 2023 – HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock . The public offering price of each share of common stock is $1.31 and the public offering price of each share of non-voting Series A-2 preferred stock is $1,310.00 . The gross proceeds to HOOKIPA from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and othe..." |
|
| 06/01/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/31/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/18/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/04/2023 |
3
| Coelho Mary Theresa (Director) has filed a Form 3 on HOOKIPA Pharma Inc. |
|